ELP1 and Riley-Day syndrome: Drug discovery campaigns have been successfully performed using neurons derived from human iPSCs, notably in AD, on Aβ1-42-induced cellular toxicity [152], ALS with TDP-43 aggregation [153] and neuron survival [154], bipolar disorder on the modulation of Wnt/β-catenin signaling [155], or familial dysautonomia on the rescued expression of IKBKAP [156].